Table 1 Patient demographics and characteristics (full analysis set)
Beta-blocker users (N = 1269) | Non-users (N = 2320) | |
|---|---|---|
Patients | ||
Age, years, mean (SD) | 68.1 (7.9) | 66.6 (8.6) |
Male, % | 64.4 | 55.5 |
White, % | 90.6 | 90.7 |
BMI, kg/m2, mean (SD) | 30.4 (6.7) | 29.1 (6.8) |
Obese (≥ 30 kg/m2), n (%) | 597 (47.0) | 913 (39.4) |
Current smoker, % | 39.8 | 45.6 |
Prior CV events, % | 67.9 | 36.7 |
Pre-BD FEV1 (mL), mean (SD) | 1215 (486) | 1213 (492) |
Post-BD FEV1% predicted, mean (SD) | 47.2 (14.2) | 48.0 (15.4) |
COPD severity, a % | ||
Moderate | 42.0 | 46.2 |
Severe | 44.5 | 38.4 |
Very severe | 11.9 | 13.5 |
COPD exacerbations in previous year, % | 60.5 | 59.8 |
≥ 2 prior COPD exacerbations, % | 16.6 | 15.1 |
Exacerbation rate in previous year, mean (SD) | 0.8 (0.9) | 0.8 (1.0) |
Prior and concomitant COPD medication, b n (%) | ||
LABA + ICS | 706 (55.6) | 1310 (56.5) |
SABA | 638 (50.3) | 1227 (52.9) |
ICS | 125 (9.9) | 200 (8.6) |
LABA | 77 (6.1) | 150 (6.5) |
Systemic corticoids | 31 (2.4) | 86 (3.7) |
SAMA | 5 (0.4) | 11 (0.5) |
SABA + SAMA | 4 (0.3) | 12 (0.5) |
LAMA | 2 (0.2) | 7 (0.3) |
Monoclonal antibody | 1 (0.1) | 0 (0.0) |
LABA + LAMA | 1 (0.1) | 1 (< 0.1) |